On Sept. 24, 2020, Lumen Bioscience and the US Army Medical Research and Development Command, announced an agreement to develop a rapid, scalable, and inexpensive biologic drug cocktail to treat gastrointestinal (GI) infection in Covid-19 patients and potentially block disease transmission.